|
|
肝内胆管癌的分子机制与治疗研究进展
|
Abstract:
肝内胆管癌(iCCA)具有发病隐匿、易转移的特点，多数患者确诊时已处于晚期。其发生发展与IDH1/2突变、FGFR2融合等关键基因改变及PI3K/AKT、Wnt/β-catenin、Hippo/YAP等信号通路异常密切相关。目前治疗以手术切除联合化疗为主，但疗效有限。近年来，针对特定分子靶点(如IDH1/2、FGFR2)的靶向药物(如培米替尼、艾伏尼布)已获批应用，为患者提供了新的治疗选择。
Intrahepatic Cholangiocarcinoma (iCCA) is characterized by insidious onset and easy metastasis. Most patients are already in the advanced stage at the time of diagnosis. Its occurrence and development are closely related to key gene alterations such as IDH1/2 mutations and FGFR2 fusions, as well as abnormalities in signaling pathways such as PI3K/AKT, Wnt/β-catenin, and Hippo/YAP. Currently, the main treatment is surgical resection combined with chemotherapy, but the efficacy is limited. In recent years, targeted drugs (such as pemigatinib and ivosidenib) targeting specific molecular targets (such as IDH1/2 and FGFR2) have been approved for use, providing new treatment options for patients.
| [1] | Rodrigues, P.M., Olaizola, P., Paiva, N.A., Olaizola, I., Agirre-Lizaso, A., Landa, A., et al. (2021) Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease, 16, 433-463. https://doi.org/10.1146/annurev-pathol-030220-020455 |
| [2] | Ilyas, S.I., Khan, S.A., Hallemeier, C.L., Kelley, R.K. and Gores, G.J. (2017) Cholangiocarcinoma—Evolving Concepts and Therapeutic Strategies. Nature Reviews Clinical Oncology, 15, 95-111. https://doi.org/10.1038/nrclinonc.2017.157 |
| [3] | Cillo, U., Fondevila, C., Donadon, M., Gringeri, E., Mocchegiani, F., Schlitt, H.J., et al. (2019) Surgery for Cholangiocarcinoma. Liver International, 39, 143-155. https://doi.org/10.1111/liv.14089 |
| [4] | Moris, D., Palta, M., Kim, C., Allen, P.J., Morse, M.A. and Lidsky, M.E. (2022) Advances in the Treatment of Intrahepatic Cholangiocarcinoma: An Overview of the Current and Future Therapeutic Landscape for Clinicians. CA: A Cancer Journal for Clinicians, 73, 198-222. https://doi.org/10.3322/caac.21759 |
| [5] | Hadfield, M.J., DeCarli, K., Bash, K., Sun, G. and Almhanna, K. (2023) Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review. International Journal of Molecular Sciences, 25, Article 543. https://doi.org/10.3390/ijms25010543 |
| [6] | Boerner, T., Drill, E., Pak, L.M., Nguyen, B., Sigel, C.S., Doussot, A., et al. (2021) Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 74, 1429-1444. https://doi.org/10.1002/hep.31829 |
| [7] | Pirozzi, C.J. and Yan, H. (2021) The Implications of IDH Mutations for Cancer Development and Therapy. Nature Reviews Clinical Oncology, 18, 645-661. https://doi.org/10.1038/s41571-021-00521-0 |
| [8] | Wu, S., Huang, J., Dong, J. and Pan, D. (2003) Hippo Encodes a Ste-20 Family Protein Kinase That Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with Salvador and Warts. Cell, 114, 445-456. https://doi.org/10.1016/s0092-8674(03)00549-x |
| [9] | Alzial, G., Renoult, O., Paris, F., Gratas, C., Clavreul, A. and Pecqueur, C. (2021) Wild-type Isocitrate Dehydrogenase under the Spotlight in Glioblastoma. Oncogene, 41, 613-621. https://doi.org/10.1038/s41388-021-02056-1 |
| [10] | Molenaar, R.J., Maciejewski, J.P., Wilmink, J.W. and van Noorden, C.J.F. (2018) Wild-Type and Mutated IDH1/2 Enzymes and Therapy Responses. Oncogene, 37, 1949-1960. https://doi.org/10.1038/s41388-017-0077-z |
| [11] | Lavacchi, D., Caliman, E., Rossi, G., Buttitta, E., Botteri, C., Fancelli, S., et al. (2022) Ivosidenib in IDH1-Mutated Cholangiocarcinoma: Clinical Evaluation and Future Directions. Pharmacology & Therapeutics, 237, Article ID: 108170. https://doi.org/10.1016/j.pharmthera.2022.108170 |
| [12] | Sumbly, V., Landry, I. and Rizzo, V. (2022) Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. Cureus, 14, e21018. https://doi.org/10.7759/cureus.21018 |
| [13] | Boulter, L. and Ebrahimkhani, M.R. (2021) Build to Understand Biliary Oncogenesis via Organoids and FGFR2 Fusion Proteins. Journal of Hepatology, 75, 262-264. https://doi.org/10.1016/j.jhep.2021.05.006 |
| [14] | Liu, S., Weng, J., Cao, M., Zhou, Q., Xu, M., Xu, W., et al. (2024) FGFR2 Fusion/Rearrangement Is Associated with Favorable Prognosis and Immunoactivation in Patients with Intrahepatic Cholangiocarcinoma. The Oncologist, 29, e1734-e1747. https://doi.org/10.1093/oncolo/oyae170 |
| [15] | Guo, B., Fan, Y., Li, D., Xia, F., Luo, C., Zhu, J., et al. (2025) Locoregional Gemcitabine plus Surufatinib and Camrelizumab in FGFR2-Non-Altered Intrahepatic Cholangiocarcinoma. Cell Reports Medicine, 6, Article ID: 102482. https://doi.org/10.1016/j.xcrm.2025.102482 |
| [16] | Katoh, M. (2018) Fibroblast Growth Factor Receptors as Treatment Targets in Clinical Oncology. Nature Reviews Clinical Oncology, 16, 105-122. https://doi.org/10.1038/s41571-018-0115-y |
| [17] | Vogel, A., Segatto, O., Stenzinger, A. and Saborowski, A. (2023) FGFR2 Inhibition in Cholangiocarcinoma. Annual Review of Medicine, 74, 293-306. https://doi.org/10.1146/annurev-med-042921-024707 |
| [18] | Angerilli, V., Fornaro, L., Pepe, F., Rossi, S.M., Perrone, G., Malapelle, U., et al. (2023) FGFR2 Testing in Cholangiocarcinoma: Translating Molecular Studies into Clinical Practice. Pathologica, 115, 71-82. https://doi.org/10.32074/1591-951x-859 |
| [19] | Aure, M.H., Symonds, J.M., Villapudua, C.U., Dodge, J.T., Werner, S., Knosp, W.M., et al. (2023) FGFR2 Is Essential for Salivary Gland Duct Homeostasis and MAPK-Dependent Seromucous Acinar Cell Differentiation. Nature Communications, 14, Article No. 6485. https://doi.org/10.1038/s41467-023-42243-0 |
| [20] | Rao, S., Goyal, A., Johnson, A., Sadashiva, N., Kulanthaivelu, K., Vazhayil, V., et al. (2024) MAPK Pathway Alterations in Polymorphous Low-Grade Neuroepithelial Tumor of the Young: Diagnostic Considerations. Brain Tumor Pathology, 41, 109-116. https://doi.org/10.1007/s10014-024-00487-8 |
| [21] | Pfaff, M.J., Xue, K., Li, L., Horowitz, M.C., Steinbacher, D.M. and Eswarakumar, J.V.P. (2016) FGFR2c-Mediated ERK-MAPK Activity Regulates Coronal Suture Development. Developmental Biology, 415, 242-250. https://doi.org/10.1016/j.ydbio.2016.03.026 |
| [22] | Riccetti, M.R., Green, J., Taylor, T.J. and Perl, A.T. (2024) Prenatal FGFR2 Signaling via PI3K/AKT Specifies the PDGFRA+ Myofibroblast. American Journal of Respiratory Cell and Molecular Biology, 70, 63-77. https://doi.org/10.1165/rcmb.2023-0245oc |
| [23] | Yang, J., Xin, C., Yin, G. and Li, J. (2023) Taraxasterol Suppresses the Proliferation and Tumor Growth of Androgen-Independent Prostate Cancer Cells through the FGFR2-PI3K/AKT Signaling Pathway. Scientific Reports, 13, Article No. 13072. https://doi.org/10.1038/s41598-023-40344-w |
| [24] | Martin-Serrano, M.A., Kepecs, B., Torres-Martin, M., Bramel, E.R., Haber, P.K., Merritt, E., et al. (2022) Novel Microenvironment-Based Classification of Intrahepatic Cholangiocarcinoma with Therapeutic Implications. Gut, 72, 736-748. https://doi.org/10.1136/gutjnl-2021-326514 |
| [25] | Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., et al. (2024) An Open-Label Study of Pemigatinib in Cholangiocarcinoma: Final Results from Fight-202. ESMO Open, 9, Article ID: 103488. https://doi.org/10.1016/j.esmoop.2024.103488 |
| [26] | Javle, M., Roychowdhury, S., Kelley, R.K., Sadeghi, S., Macarulla, T., Weiss, K.H., et al. (2021) Infigratinib (BGJ398) in Previously Treated Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Mature Results from a Multicentre, Open-Label, Single-Arm, Phase 2 Study. The Lancet Gastroenterology & Hepatology, 6, 803-815. https://doi.org/10.1016/s2468-1253(21)00196-5 |
| [27] | Liu, L., He, Y., Dong, P., Ma, L., Wang, Z., Liu, X., et al. (2016) Protein Tyrosine Phosphatase PTP4A1 Promotes Proliferation and Epithelial-Mesenchymal Transition in Intrahepatic Cholangiocarcinoma via the PI3K/AKT Pathway. Oncotarget, 7, 75210-75220. https://doi.org/10.18632/oncotarget.12116 |
| [28] | Zhu, X., Song, X., Xie, K., Zhang, X., He, W. and Liu, F. (2017) Osthole Induces Apoptosis and Suppresses Proliferation via the PI3K/Akt Pathway in Intrahepatic Cholangiocarcinoma. International Journal of Molecular Medicine, 40, 1143-1151. https://doi.org/10.3892/ijmm.2017.3113 |
| [29] | Xie, K., Nian, J., Zhu, X., Geng, X. and Liu, F. (2015) Modulatory Role of Garlicin in Migration and Invasion of Intrahepatic Cholangiocarcinoma via PI3K/AKT Pathway. International Journal of Clinical and Experimental Pathology, 8, 14028-14033. |
| [30] | Song, F., Chen, F., Wu, S., Hu, B., Liang, X., Yang, H., et al. (2021) Mucin 1 Promotes Tumor Progression through Activating Wnt/β-Catenin Signaling Pathway in Intrahepatic Cholangiocarcinoma. Journal of Cancer, 12, 6937-6947. https://doi.org/10.7150/jca.63235 |
| [31] | Wei, Y., Chen, W., Li, Z., Xie, K. and Liu, F. (2022) EIF3H stabilizes CCND1 to Promotes Intrahepatic Cholangiocarcinoma Progression via Wnt/β‐Catenin Signaling. The FASEB Journal, 36, e22647. https://doi.org/10.1096/fj.202200913r |
| [32] | Zhang, H., Dong, X., Ding, X., Liu, G., Yang, F., Song, Q., et al. (2023) Bufalin Targeting CAMKK2 Inhibits the Occurrence and Development of Intrahepatic Cholangiocarcinoma through Wnt/β-Catenin Signal Pathway. Journal of Translational Medicine, 21, Article No. 900. https://doi.org/10.1186/s12967-023-04613-6 |
| [33] | Zhang, Y., Xu, H., Cui, G., Liang, B., Chen, X., Ko, S., et al. (2022) β-Catenin Sustains and Is Required for Yes-Associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 163, 481-494. https://doi.org/10.1053/j.gastro.2022.04.028 |
| [34] | Taniguchi, K., Wu, L., Grivennikov, S.I., de Jong, P.R., Lian, I., Yu, F., et al. (2015) A Gp130-Src-YAP Module Links Inflammation to Epithelial Regeneration. Nature, 519, 57-62. https://doi.org/10.1038/nature14228 |
| [35] | Kim, S.H. and Park, J. (2019) IDH2 Deficiency Impairs Cutaneous Wound Healing via Ros-Dependent Apoptosis. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1865, Article ID: 165523. https://doi.org/10.1016/j.bbadis.2019.07.017 |
| [36] | Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R.E., Longarini, R., Stagno, A.M., et al. (2022) Clinical Treatment of Cholangiocarcinoma: An Updated Comprehensive Review. Annals of Hepatology, 27, Article ID: 100737. https://doi.org/10.1016/j.aohep.2022.100737 |
| [37] | Roy, S., Glaser, S. and Chakraborty, S. (2019) Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms. Frontiers in Medicine, 6, Article 293. https://doi.org/10.3389/fmed.2019.00293 |
| [38] | Fong, Z.V., Brownlee, S.A., Qadan, M. and Tanabe, K.K. (2021) The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Annals of Surgical Oncology, 28, 2660-2674. https://doi.org/10.1245/s10434-021-09671-y |
| [39] | Park, J.O., Oh, D., Hsu, C., Chen, J., Chen, L., Orlando, M., et al. (2015) Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Research and Treatment, 47, 343-361. https://doi.org/10.4143/crt.2014.308 |
| [40] | Oh, D., He, A.R., Bouattour, M., Okusaka, T., Qin, S., Chen, L., et al. (2024) Durvalumab or Placebo Plus Gemcitabine and Cisplatin in Participants with Advanced Biliary Tract Cancer (TOPAZ-1): Updated Overall Survival from a Randomised Phase 3 Study. The Lancet Gastroenterology & Hepatology, 9, 694-704. https://doi.org/10.1016/s2468-1253(24)00095-5 |
| [41] | Sarabi, M. and Artru, P. (2025) Biliary Tract Cancers: Topaz-1 Up-Date, a Practice Changing Study. Hepatobiliary Surgery and Nutrition, 14, 1009-1011. https://doi.org/10.21037/hbsn-2025-367 |
| [42] | Burris, H.A., Okusaka, T., Vogel, A., Lee, M.A., Takahashi, H., Breder, V., et al. (2024) Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1): Patient-Reported Outcomes from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 25, 626-635. https://doi.org/10.1016/s1470-2045(24)00082-2 |
| [43] | Wang, J., Xu, Y., Hong, B., Hou, Q., Chen, W., Zhang, W., et al. (2025) PD-1/PD-L1 Inhibitors Plus Chemotherapy versus Chemotherapy Alone as the First Line Treatment for Advanced Biliary Tract Cancer: A Pooled Analysis of KEYNOTE-966 and TOPAZ-1 Trails. World Journal of Surgical Oncology, 23, Article No. 228. https://doi.org/10.1186/s12957-025-03877-0 |
| [44] | Almhanna, K. (2024) Immune Checkpoint Inhibitors in Combination with Chemotherapy for Patients with Biliary Tract Cancer: What Did We Learn from TOPAZ-1 and Keynote-966. Translational Cancer Research, 13, 22-24. https://doi.org/10.21037/tcr-23-1763 |
| [45] | Igata, Y., Kudo, M., Kojima, M., Kami, S., Aoki, K., Satake, T., et al. (2024) Conversion Surgery after Gemcitabine and Cisplatin Plus Durvalumab for Advanced Intrahepatic Cholangiocarcinoma: A Case Report. World Journal of Clinical Cases, 12, 6721-6727. https://doi.org/10.12998/wjcc.v12.i34.6721 |
| [46] | Phuna, Z.X., Kumar, P.A., Haroun, E., Dutta, D. and Lim, S.H. (2024) Antibody-Drug Conjugates: Principles and Opportunities. Life Sciences, 347, Article ID: 122676. https://doi.org/10.1016/j.lfs.2024.122676 |
| [47] | Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., et al. (2025) Antibody-Drug Conjugates (ADCs): Current and Future Biopharmaceuticals. Journal of Hematology & Oncology, 18, Article No. 51. https://doi.org/10.1186/s13045-025-01704-3 |
| [48] | Macarulla, T., Neuzillet, C., Prager, G.W., Rimassa, L. and Bridgewater, J. (2025) Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review. Oncology and Therapy, 13, 939-962. https://doi.org/10.1007/s40487-025-00370-2 |
| [49] | Ballestín, P., López de Sá, A., Díaz-Tejeiro, C., Paniagua-Herranz, L., Sanvicente, A., López-Cade, I., et al. (2025) Understanding the Toxicity Profile of Approved ADCs. Pharmaceutics, 17, Article 258. https://doi.org/10.3390/pharmaceutics17020258 |
| [50] | Bao, X., Chen, Z., Xiong, J., Yang, Z. and Zhang, N. (2025) Advanced Cholangiocarcinoma with Human Epidermal Growth Factor Receptor 2 (HER2) Amplification Treated with Trastuzumab Deruxtecan (T-DXd): A Case Report. Medicine, 104, e44094. https://doi.org/10.1097/md.0000000000044094 |
| [51] | Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., et al. (2024) Tisotumab Vedotin as Second-or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine, 391, 44-55. https://doi.org/10.1056/nejmoa2313811 |
| [52] | Song, X., Li, R., Wang, H., Song, P., Guo, W. and Chen, Z. (2022) Tisotumab Vedotin for the Treatment of Cervical Carcinoma. Drugs of Today, 58, 213-222. https://doi.org/10.1358/dot.2022.58.5.3400745 |
| [53] | Markham, A. (2021) Tisotumab Vedotin: First Approval. Drugs, 81, 2141-2147. https://doi.org/10.1007/s40265-021-01633-8 |
